Listing of Claims

1-12. Cancelled

13. (Currently Amended) A method for lowering elevated or maintaining lowered serum parathyroid hormone levels in the human suffering from treating a human to alleviate or prevent the pathological effects of hyperparathyroidism secondary to end stage renal disease, comprising administering by a route selected from the group consisting of subcutaneous injection, intramuscular injection, intravenous injection, nasopharyngeal absorption, mucosal absorption and transdermal absorption, a non-oral dosage form to a human in need thereof a vitamin D analog selected from the group consisting of 1α-OH-vitamin D₂, 1α-OH-vitamin D₄, and 1α,24(R)-(OH)₂-vitamin D₄, wherein the analog is administered to the human in an amount sufficient to lower elevated or maintain lowered serum parathyroid hormone levels in the human to thereby alleviate or prevent the pathological effects.

14. Cancelled

- 15. (Previously Presented) The method of claim 13 wherein the analog is administered in combination with at least one agent characterized by the agent's ability to reduce loss of bone mass, or bone mineral content in the human.
- 16. (Previously Presented) The method of claim 15 wherein the agent is selected from the group consisting of other vitamin D compounds, conjugated estrogens, sodium fluorides, biphosphonates, cobalamin, pertussin toxin or boron.
- 17. (Previously Presented) The method of claim 13 wherein the analog is administered in a dosage amount of from about 1 µg to about 100 µg per week.
- 18. (Previously Presented) The method of claim 13 wherein said analog is administered parenterally in a dosage amount of about 1 µg to 30 µg given 1 to 3 times per week.
- 19. (Previously Presented) The method of claim 13, wherein the analog is co-administered with a calcium-based phosphate binder.

Appl. No. 10/766,749 Amdt. dated August 11, 2005 Reply to Office action of March 11, 2005

20. (Previously Presented) The method of claim 13, wherein the analog is 1α -OH-vitamin